A pharmaceutical company needed support in establishing a Confirmatory Testing Committee as part of their Nitrosamine Project, ensuring consistent and effective oversight throughout the testing process. They required guidance on defining the committee’s roles and responsibilities, selecting qualified members, and setting clear decision-making protocols. This involved creating a structured meeting schedule, standardizing documentation practices, and implementing a robust tracking system to follow up on action items. By seeking external help, the company aimed to gain transparency, maintain regulatory compliance, and ensure timely responses to any confirmatory testing results or recommendations issued by the committee.
We assist pharmaceutical teams in assessing and managing nitrosamines risks by aligning processes with ICH M7 requirements and current regulatory expectations.
Organizations define a formal governance structure that assigns clear roles to QA, analytical experts, and regulatory specialists. First, they establish decision authority for each role. Then, they standardize evaluation criteria for test results and escalation rules. As a result, the committee eliminates ambiguity in prioritization and ensures faster, more consistent decisions across all testing outcomes.
The most effective approach is to implement a controlled communication framework with a designated liaison and standardized reporting templates. In addition, teams schedule fixed update cycles and define response-time expectations for critical findings. Therefore, manufacturing units receive validated decisions quickly and can execute actions without interpretation gaps or regulatory risk.
